Modern Clinical Trials Spotlight

By Ori Ben-Yehuda, MD

Curbside Consult: The Biggest Clinical Trial Innovation Needs in…

Physicians consider priorities for future clinical trials in their respective interventional cardiology areas of focus, with responses spanning from a need for data informing treatment benefit and decision-making for current and future therapies to broader changes needed in the approach to research.

With Mirvat Alasnag, MD, FACC, FACP, FSCAI, FRCP; Salvatore Brugaletta, MD, PhD; Jay Giri, MD, MPH, FACC, FAHA, FSCAI; Rasha Al-Lamee, MA, MBBS, FRCP, PhD; Rishi Puri, MD, PhD, FRACP; and Gagan D. Singh, MD

What Are Three Keys to Improving Equity in Cardiac Clinical Trials?

Leaders in cardiac clinical trial research offer their thoughts on how to support and progress the efforts to increase equity among clinical trials.

With F. Aaysha Cader, MD, MRCP, MSc, FACC, FSCAI; Marion Mafham, MBChB, FRCP, MD; Megan Coylewright, MD, MPH, FSCAI, FACC; and Celina M. Yong, MD, MBA, MSc

Less Invasive Ventricular Enhancement: The LIVE Procedure and Design of the ALIVE Trial

An overview of left ventricular reconstruction with the Revivent TC system as an alternative to conventional surgical ventricular reconstruction for treatment of ischemic heart failure, with a look at lessons learned from the STICH trial and a rundown of the ALIVE trial.

By Romy R.M.J.J. Hegeman, MD; Martin J. Swaans, MD, PhD; and Patrick Klein, MD, PhD

OCT-Guided PCI: Lessons From the ILUMIEN IV: OPTIMAL PCI Trial

A discussion of study design, insights into the results, and the current and future role of OCT-guided stent implantation and optimization.

By Ziad A. Ali, MD, DPhil; Doosup Shin, MD; and Richard A. Shlofmitz, MD

Rapamycin-Eluting Coronary Stent for PCI: The TARGET IV Trial

A review of the TARGET IV trial evaluating the Firehawk rapamycin-eluting cobalt chromium coronary stent system. Can this new stent increase healing time, reduce adverse events, and eliminate the need for prolonged dual antiplatelet therapy?

By Christiana O. Oshotse, BA, and Robert W. Yeh, MD, MSc, MBA

COAPT 5-Year Data Demonstrate Benefits of Mitral TEER, Reveal Need to Address Underlying LV Dysfunction

With commentary from Gregg Stone, MD

Study of Medicare Population Demonstrates Racial and Ethnic Disparities in Aortic Stenosis Management and Outcomes

With commentary from Michael P. Thompson, PhD

Renal Denervation: Where We Stand After the FDA Panels

Experts’ thoughts on what defines a clinically meaningful reduction in blood pressure, roles of office-based and ambulatory blood pressure monitoring, ideal candidates for renal denervation and patient preference as a driver for the procedure, options that could meet the FDA's request for more data, and applying a team-based approach to screening and treatment.

With Ajay J. Kirtane, MD, SM; Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM; and Taisei Kobayashi, MD

Compensation and Production Trends for Interventionalists: A Shifting Subspecialty in a Postpandemic World

Despite staffing issues and pandemic challenges, cardiovascular specialties remain stable and show promise for the future.

By Joel Sauer, MBA

An Interview With Geoffrey D. Barnes, MD, MSc

The University of Michigan vascular cardiologist discusses PERT research needs, implementation science in practice, anticoagulation stewardship, and collaborative patient care.